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Abstract
Background: Dexamethasone (DEX) is used for the treatment of various inner ear diseases. However, the molecular
mechanism of DEX on gentamicin induced hair cell damage is not known. Therefore, this study investigated the
protective effect of DEX on gentamicin (GM)-induced ototoxicity and the effect of GM on the expression of
apoptosis related genes.
Methods: The protective effects of DEX were measured by phalloidin staining of explant cultures of organ of Corti
from postnatal day 2–3 mice with GM-induced hair cell loss. Terminal deoxynucleotidyl transferase dUTP nick end
labeling staining was used to detect apoptosis and immunofluorescence was done to analyze the effect of DEX on
the expression of apoptosis related genes.
Results: Cochlear explant cultures of postnatal day-4-old mice were exposed to 0, 1, 5, 10, 30, 50, and 100 μg/ml
DEX and GM during culture. DEX protected from GM-induced hair cell loss in the inner ear of postnatal day 4 mice.
To understand the molecular mechanisms by which DEX pre-treatment decreased hair cell loss, the testes of
cochlear explant cultures of postnatal day 4 mice were examined for changes in expression of cochlear apoptosis
mediators. The pro-apoptotic protein Bax was significantly down-regulated and numbers of apoptotic hair cells
were decreased.
Conclusions: DEX has a protective effect on GM-induced hair cell loss in neonatal cochlea cultures and the
protective mechanism may involve inhibition of the mitochondrial apoptosis pathway. The combination with
scaffold technique can improve delivery of DEX into the inner ear to protect GM-induced ototoxicity.
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Background
Aminoglycosides remain important antibiotics in current
clinical practice and are widely used globally. Their anti-
bacterial effect includes enterococcus, mycobacteria, and
especially multi-drug-resistant Gram-negative bacteria
[1]. However, their clinical usefulness is limited by their
ototoxicity and nephrotoxicity [2]. Aminoglycosides
cause ototoxicity in 2–25% of patients and if high-
frequency hearing loss is tested, half of all patients may
be affected [3]. The exact mechanism of GM-induced
ototoxicity is unclear. The main signal transduction
pathway of hair cell damage is ROS production and
resulting apoptosis [1, 4]. One signaling pathway activated
by aminoglycosides via ROS is the c-Jun N-terminal
kinase (JNK) pathway, which contributes to cell apoptosis
[5]. One of the downstream targets of JNK is the
transcription factor, activating protein-1, the main compo-
nent of which is c-Fos protein [6].
Gentamicin (GM), which is one of the most commonly
used aminoglycoside antibiotics, can induce hearing loss
and balance disturbance due to the destruction of cochlear
and vestibular hair cells [7]. The exact mechanism of GM-
induced ototoxicity is unclear. The main signal transduc-
tion pathway of hair cell damage involves reactive oxygen
species (ROS) production and resulting apoptosis [1, 4].
Protection of hair cell damage is an important target for
the prevention of sensory neural hearing loss. However,
few clinical agents are available for the treatment of
ototoxicity-related sensory neural hearing loss.* Correspondence: jjsong23@gmail.com3Department of Otorhinolaryngology-Head and Neck Surgery, Korea
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Dexamethasone (DEX) is a synthetic steroid analog used
for the treatment of various inner ear diseases including
sudden idiopathic sensory neural hearing loss, Meniere’s
disease and Bell’s palsy. However, the exact biological
mechanism of DEX is unclear. In animal models, intra-
tympanic administration of DEX protected against
cisplatin-induced ototoxicity [8, 9]. However, the molecu-
lar mechanism of protective effect of DEX on GM-
induced hair cell damage is not known. DEX improves
oxidative energy metabolism of brain mitochondria and
stimulates ATP synthesis by increasing mitochondrial en-
zymes [10, 11]. Mitochondria are the primary site of oxi-
dative metabolism and apoptosis. The intrinsic pathway of
apoptosis is activated by cytochrome c release from mito-
chondria, mediated by the opening of the mitochondrial
permeability pore [12].
We hypothesized that DEX can lessen apoptosis by
modulating the activity of apoptosis-related genes, which
in turn modulates the mitochondrial membrane perme-
ability to molecules including Bax. The purpose of this
study was to investigate the protective effect of DEX on
GM-induced ototoxicity and the effect of DEX on the
expression of apoptosis-related genes.
Methods
Explant model
Cochlea organotypic cultures were made as described pre-
viously [13]. All protocols were in accordance with the
guidelines of the Animal Care Ethics Committee of
Dongguk University Ilsan Hospital guidelines. ICR mouse
(Koatech, Pyeongtaek, Gyeonggi, Korea) pups were decap-
itated on postnatal day 4. The cochlea of each mouse was
carefully dissected as a flat-surface preparation of the
organ of Corti. A drop of 3.86 mg/mLType I rat tail colla-
gen (BD Biosciences, Piscataway, NJ, USA) was added to a
solution containing 0.02 N acetic acid, 10x basal medium
Eagle’s medium (Sigma-Aldrich, St. Louis, MO, USA), and
2% sodium carbonate in a 9:1:1 ratio in a 35 mm-diameter
culture dish (Nunc, Rochester, NY, USA) and allowed to
gel. Afterwards, 1 mL of serum-free Dulbecco’s modified
Eagle’s medium (Welgene, Daegu, Korea) supplemented
with 1% N-1 supplement (Sigma-Aldrich) and 50 U/mL
penicillin G (Sigma-Aldrich) was added. The organ of
Corti was gently pressed onto the surface of the collagen
gel with forceps and held in place by the surface tension
of the culture medium. Cochlea cultures were incubated
at 37°C in a humidified atmosphere of 5% CO2 overnight.
Various concentrations of DEX were used in a 24-h pre-
treatment prior to a 24-h exposure to a medium contain-
ing 0.3 mM GM.
After incubation for 24 h, the cultures were fixed,
permeabilized, and stained with Alexa Fluor 350 phal-
loidin (Invitrogen, Carlsbad, CA, USA). The explants
were then mounted on a slide with Flurogel in tris buffer
(Electron Microscopy Sciences, Hatfield, PA, USA), cov-
erslipped, and examined with a DP70 fluorescence
microscope (Olympus, Tokyo, Japan). Each labeled hair
cell cilia was counted in the three outer hair cells (OHC)
rows and one inner hair cell (IHC) row. Cells were con-
sidered to be missing if there was a gap in the normal
geometric array and no stereocilia or cuticular plates
were apparent. The number of cells was counted over a
distance of 100 μm from five randomly selected fields
for the basal, middle, and apical turns of each explant.
The average from five fields was considered as a single
sample, and typically 5–11 specimens were evaluated for
each condition.
Terminal deoxynucleotidyltransferase dUTP nick end
labeling (TUNEL)
The anti-apoptosis effect was assessed using the TUNEL
assay. DNA fragmentation was assessed in situ using a
fluorescein-based In situ cell death detection kit (Roche,
Penzberg, Bayern, Germany) as described by the manu-
facturer, with minor modifications. Fixed cochlea orga-
notypic cultures were placed in 0.01 M phosphate
buffered saline (PBS) for 10 min, and treated with 0.03%
Triton X-100 for at least 15 min at room temperature.
After washing twice with deionized water for 2 min,
each culture was immersed in 1× TdT labeling buffer for
5 min. The cultures were incubated in TUNEL mix con-
taining 50× TdT dNTP, 50× cation (Mg2+), 50× TdT en-
zyme, and 1× TdT labeling buffer for 60 min at 37°C in
a humidity chamber. The reaction was terminated by
washing in 1× TdT stop buffer for 5 min. The cultures
were washed in 0.05% PBS-Tween 20 (PBS-T), before
being mounted on glass with coverslips using Tris buffer
containing flourogel (Electron Microscopy Sciences).
Samples were viewed using a fluorescence microscope
using a 495 nm filter.
Immunofluorescence staining for Bax
For Bax labeling, the cultures were fixed and perme-
abilized. Nonspecific staining was blocked with 2.5%
normal donkey serum (Sigma-Aldrich) for 30 min at
room temperature. The cultures were then incubated
with Bax rabbit polyclonal IgG (200 μg/mL, 1:200 dilu-
tion; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
in PBS for 24 h at 4°C followed by Alexa Fluor® 594 don-
key anti-rabbit IgG (1:500 dilution; Molecular Probes,
Eugene, OR, USA). All cultures were counterstained
with Hoechst 33342 (Molecular Probes) for 3 min.
The samples were mounted on a slide with fluorogel
(Electron Microscopy Sciences), coverslipped, and ex-
amined with a model DP70 fluorescence microscope
(Olympus). Samples were viewed using a fluorescence
microscope using a 488nm filter and 594 nm filter.
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Results
Protective effect of DEX on GM-induced hair cell loss
Cochlear cultures from postnatal mice were pretreated
with medium containing DEX at concentrations of 0, 1, 5,
10, 30, 50, and 100 μg/mL and then exposed to a medium
containing 0.3 mM GM for 24 h. The specific concentra-
tion of GM (0.3 mM) to affect inner or outer HC loss was
determined from our previous works [1, 14]. Compared
with the control group, IHCs and OHCs of the organ of
Corti in the GM-only group were destroyed. Viable
phalloidin-labeled hair cells were counted and shown in
Fig. 1. A dose-dependent protective effect of DEX was evi-
dent. Compared to use of GM alone, pretreatment with
DEX concentrations exceeding 5 ug/mL were significantly
protective (p < 0.005; Fig. 1). The images of phalloidin
stained cochlear explant also showed that DEX pretreat-
ment reduced the GM-induced ototoxicity in a dose-
dependent manner. GM alone group severely distorted
the anatomy of the organ of corti, compared with un-
treated controls. However, above 5 ug/mL of DEX effect-
ively provided protection against GM-induced ototoxicity.
The alignment of bundles in the organ of Corti was
retained their shape by the highest DEX (300 μg/mL) pre-
treatment in GM-induced ototoxicity (Fig. 2). Taken to-
gether, these results indicated that DEX was significantly
protective against GM-induced hair cell loss.
TUNEL assay and Immunofluorescence (IFC)
The influence of DEX pretreatment on cochlear apop-
tosis induced by GM was assessed using the TUNEL
assay. TUNEL-positive cells (green fluorescence follow-
ing counterstaining with Myosin 7a) were clearly de-
creased at higher doses of DEX, especially for hair cells
(Fig. 3A). DEX pretreatment inhibited GM-induced
apoptosis in a dose-dependent manner in IHCs and
OHCs in cochlear explants cultures. At concentrations
above 5 μg/mL, DEX pretreatment showed an anti-
apoptotic effect in IHCs and OHCs (Fig. 3B; p < 0.005).
Since pro-apoptotic proteins in the Bcl-2 family are crit-
ical in regulating cell death and survival of diverse spe-
cies, we next assessed if expression of any particular
members of the pro-apoptotic Bcl-2 family were affected
by DEX. Immunofluorescence analyses for Bax in coch-
lear explant cultures from P4 mice revealed decreased
expression in cochlear hair cells in a DEX dose-
dependent manner (Fig. 4).
Discussion
This study investigated the protective effects of DEX on
GM-induced hair cell loss and the expression of apoptosis-
related genes in neonatal mouse cochlea cultures. DEX pro-
tected against GM-induced hair cells loss in a dose-
dependent manner and modulated the expression of Bax.
Many agents include sodium thiosulphate [15], N-acetyl
cysteine [16], alpha tocopherol [17], L-methionine [18], and
gingko biloba [19] have been studied to find otoprotectants.
Glucocorticoids including prednisone, dexamethasone, and
methylprednisolone are often used for the treatment of
various inner ear diseases including autoimmune inner ear,
ehdolymphatic hydrops, Meniere’s disease, tinnitus, and
Fig. 1 Protective effect of DEX against GM-induced hair cell loss in organotypic cochlear cultures from postnatal mice. GM induced hair cell loss
in the control (Con) group and DEX had a significant effect at concentrations higher than 5 μg/mL. p < 0.005 as compared with the GM-alone
group; p < 0.05*, p < 0.005**, p < 0.0005***)
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sudden sensorineural hearing loss [20]. Also, DEX protects
against various types of inner ear damage including acoustic
trauma and ototoxicity [21, 22].
Though the exact molecular mechanism of protective
effect of DEX is not known, DEX is thought to function
via its glucocorticoid receptor and signal transduction
pathway mediating inflammation and apoptosis by the
modulation of nuclear factor kappa B (NFkB) in the
inner ear [23] and by limiting the formation of ROS in
the inner ear [24]. The presence of corticosteroid recep-
tors in the mouse inner ear provides further evidence
that steroids can exert an effect on the inner ear [25].
Systemic injection of DEX is reportedly effective in
preventing cisplatin-induced ototoxicity [26]. Intratym-
panic administration of DEX protects against cisplatin-
induced ototoxicity in animal models [8, 9, 27, 28]. We
have also shown that DEX significantly protect against
GM-induced hair cells loss in vivo in a dose-dependent
manner (Figs.1 and 2). Especially, the high concentration
of DEX (300 μg/mL) showed complete protection
against GM-induced ototoxicity (Fig. 2).
In the naïve organ of Corti explants treated with DEX,
TNFR1 expression was reduced, Bcl-2 and Bcl-xl expres-
sion were increased, and Bax/Bcl-2 ratio was decreased
[29]. In our study, the critical concentration of GM af-
fected apoptosis of hair cells in the organ of Corti which
was determined using TUNEL assay (Fig. 3). DEX pre-
treatment significantly reduced GM induced cochlear
apoptosis above 5 μg/mL (Fig. 3). In addition, we have
evaluated that DEX decreased the expression of apop-
totic activator such as Bax when GM induced apoptosis
in cochlear hair cells (Fig. 4). GM-induced ototoxicity
results in the activation of intrinsic apoptotic pathway
mediated by the change of mitochondrial membrane
permeability [30]. Bcl2 family protein, a mitochondrial
membrane protein, functions as a checkpoint for cell
death and survival signals in the mitochondria. These
proteins control the permeability of the mitochondrial
membrane and leakage of cytochrome-c, which activates
the upstream caspase [30]. The balance of pro- and anti-
apoptotic proteins of the Bcl2 protein family is import-
ant for the initiation of apoptosis. Anti-apoptotic Bcl-2
proteins are able to bind to pro-apoptotic Bcl-2 proteins,
neutralizing the pro-apoptotic signal [31]. However,
when the balance moves in favor of apoptosis, the pro-
apoptotic cytoplasmic Bcl-2 member Bax translocates to
the mitochondria, causing pores in the mitochondrial
Fig. 3 Decreased apoptosis in organotypic cochlear cultures of P4 mice exposed to GM and DEX. A. TUNEL assay was conducted on explant cultures
of P4 mice cochlea prepared from groups treated with PBS only (a), 0.3 mM GM only (b), and following pretreatment with DEX concentrations of 5
μg/mL (c), 100 μg/mL (d) prior to GM exposure. B. Apoptotic hair cells (green fluorescence) were counted from the cochlear explant cultures of P4
mice. Data are mean ± SEM from three independent tests in each dose of pre-treated DEX with 0.3 mM GM. p < 0.05 as compared with the GM-alone
group. (p < 0.05* and p < 0.005**, 400x magnification.)
Fig. 2 Cochlea histology in mice exposed to 0.3 mM GM and dose-
dependence of DEX treatment. Phalloidin stained cochlear explant
cultures of postnatal day-4-old mice pretreated with PBS (a), 0.3 mM GM
only (b), 1 μg/mL DEX (c), 5 μg/mL DEX (d), 10 μg/mL DEX (e), 30 μg/
mL DEX (f), 50 μg/mL DEX (g), and 300 μg/mL DEX (h)
(400x magnification)
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membrane and release of cytchome c. Therefore, our
study demonstrated that DEX suppressed apoptosis of
hair cells in the cochlear by regulation of Bax expression
in GM-induced ototoxicity model.
In the ototoxicity model, Dinh et al. has shown that
DEX has preventive effect against TNF-α induced oto-
toxicity in organ of Corti explants [32], suggesting the
anti-inflammatory effect of DEX. Future studies need to
determine whether DEX can protect against pro-
inflammatory pathway associated with GM ototoxicity.
In addition, the development of DEX delivery system
into the inner ear are also important to investigate as
well. For example, combination with scaffold system like
DEX-eluting nanoparticles with hydrogel that may be
helpful to deliver prolonged levels of DEX in the coch-
lear as a drug delivery system (DDS).
Conclusion
We investigated the protective effects of DEX on GM-
induced hair cell loss in neonatal mouse cochlea cul-
tures. The pretreatment of DEX decreased the expres-
sion of pro-apoptotic Bax protein which might protect
the mitochondrial apoptosis pathway on GM-induced
ototoxicity. Taken together our study provides the pro-
tective mechanism of DEX in an ototoxicity model.
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